AI-personalized Medilepsy app to help teens and young adults with epilepsy manage medicines and transition to adult care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares an AI-personalized version of the Medilepsy chatbot app with a standard non-AI version among underserved adolescents and young adults with epilepsy aged 14–24 in Florida. Participants must be prescribed anti-seizure medications, be English-fluent, own an internet-capable mobile device, and receive outpatient care at participating sites. The apps deliver reminders, education, and transition-readiness support, with primary endpoints focused on medication adherence and transition readiness, secondary endpoints on usability, and exploratory endpoints on language experience. Enrollment and interventions take place at Orlando Health and University of Central Florida outpatient locations, with parental involvement for minors as required.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with epilepsy
* Currently prescribed anti-seizure medicine (ASMs)
* Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
* Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
* Are between 18-24 years old and able to provide informed consent
* Able to read, speak, and write in English
* Resides in Florida
* Receive outpatient medical services

Exclusion Criteria:

* They do not own a mobile device with internet access.
* They have a history of severe intellectual disability.
* They are unable to operate a mobile device (keyboard or touchscreen).
* Reside in an in-patient setting.
* Adults unable to consent.
* Pregnant women (excluded because pregnancy is not relevant to the study focus).
* Prisoners.

Where it's running

• Orlando Health Arnold Palmer Hospital
  Orlando, Florida, United States Recruiting
• Orlando Health Orlando Regional Medical Center
  Orlando, Florida, United States Recruiting

Study contacts

• Principal investigator: Michelle Tall, PhD, RN, FAES — University of Central Florida
• Study coordinator: Michelle Tall, PhD, RN, FAES
• Email: Michelle.Tall@UCF.edu
• Phone: 4077970555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Project PENGUIN: Profiling phenotypic, epigenetic, and neurogenetic traits in rare neurodevelopmental disorders

  This project will try to collect clinical data, genetic and epigenetic samples, imaging, and skin-derived cell models from people with rare neurogenetic disorders like SYT1/BAGOS to help track disease and support future treatments.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07329257

• Long-term RAP-219 treatment for adults with focal onset seizures

  This trial will try RAP-219, an investigational anti-seizure medication, in adults with refractory focal seizures to see if it is safe long-term and helps reduce seizures.

  Recruiting at 7 sites Phase 2 Rapport Therapeutics Inc. · Boise, Idaho and 6 other locations · NCT07219407

• Vascular risk screening and management after late-onset seizures

  This project will test whether screening and treating blood pressure, cholesterol, BMI and other vascular risks in people who have their first unprovoked seizure after age 50 can lower their future risk of stroke and heart disease.

  Recruiting at 3 sites Sahlgrenska University Hospital · Borås and 2 other locations · NCT07116330

• Detecting thalamus seizures using a Percept deep brain stimulator

  This project will test whether the Medtronic Percept DBS device can reliably detect seizures from the thalamus in adults with drug-resistant epilepsy.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06700356

• Optimizing brain stimulation for epilepsy treatment

  This study is testing whether low or high frequency brain stimulation can help people with epilepsy control their seizures better.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06617845

• Low-intensity focused ultrasound treatment for drug-resistant epilepsy

  This study is testing if low-intensity focused ultrasound can help people with drug-resistant temporal lobe epilepsy have fewer seizures while they continue taking their regular medications.

  Recruiting at 3 sites Phase 1/2 NaviFUS Corporation · Palo Alto, California and 2 other locations · NCT06388707

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.